A.V. KILDYUSHEVSKY, S.V. KOTOV, O.P. SIDOROVA, A.V. BORODIN, M.S. BUNAK

 Moscow Regional Research and Clinical Institute named after M.F. Vladimirskiy, Moscow

Contact details:

Sidorova O.P. — MD, Professor of the Department of Neurology

Address: 61/2 Shchepkin St., 129110 Moscow, Russian Federation, tel.: +7-9680913-12-13, e-mail: sidorovaop2019@mail.ru

Extracorporeal photopheresis (extracorporeal photochemotherapy, extracorporeal photoimmunotherapy, or simply photopheresis) is a therapy based on exposure of peripheral blood leukocytes to ultraviolet radiation. A night incubation period is added to increase the efficiency of extracorporeal photopheresis. This modification of extracorporeal photopheresis is called «transimmunization». It induces the transformation of treated monocytes into cells expressing the phenotypic and functional features of dendritic antigen-presenting cells. Initially developed to treat cutaneous T-cell lymphoma, extracorporeal photopheresis has also proved effective in the treatment of graft-versus-host reactions, autoimmune diseases, and coronavirus infection, which is characterized by the development of autoimmune reactions.

The purpose — to determine the effectiveness of transimmunization in patients with remitting multiple sclerosis using the NEDA-3 index for 3 years of treatment.

Material and methods. 12 adult patients with remitting multiple sclerosis underwent transimmunization twice in a week every month for 6 months. Subsequently, the interval was increased each time by 1 month. Then the transimmunization was carried out twice a year. After 3 years from the start of treatment, the condition of patients was assessed using the criterion of «absence» of signs of disease activity (NEDA-3). The EDSS scale and MRI of the brain were used.

Results. During the entire three-year treatment period, NEDA-3 was registered in 5 out of 12 patients (41,67%).

Conclusion. Transimmunization (modification of extracorporeal photopheresis) had a positive effect on the condition of patients with remitting course of multiple sclerosis. The method can be used along with other methods of treating the disease to prevent disability of patients and improve their quality of life.

Key words: extracorporeal photopheresis, extracorporeal photochemotherapy, extracorporeal photoimmunotherapy, photopheresis, transimmunization, multiple sclerosis.

REFERENCES

1. Knobler R., Berlin G., Calzavara-Pinton P. et al. Guidelines on the use of extracorporeal photopheresis. JEADV, 2014, vol. 28 (1), pp. 1–37.
2. Alvero A.B., Hanlon D., Pitruzzello M. et al. Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer. Oncoimmunology, 2020, vol. 9 (1), p. 1758869.
3. Edelson R., Berger C., Gasparro F., et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary Results N Engl. J. Med, 1987, vol. 316, pp. 297–303.
4. Greinix H., Sureda A., Corbacioglu S. et al. Photopheresis in adults and pediatrics. In: The EBMT Handbook: hematopoietic cell transplantation and cellular therapies [Internet]. 8th edition. Cham (CH): Springer; 2024. Ch. 66. Pp. 587–593.
5. Lin Y., Cheng Z., Zhong Y. et al. Extracorporeal photopheresis reduces inflammation and joint damage in a rheumatoid arthritis murine model. J. Transl. Med, 2024, vol. 22 (1), p. 305.
6. Ruf T., Rahimi F., Anz D. et al. Extracorporeal Photopheresis as a Treatment Option for Immune-Related Adverse Events: Two Case Reports and a Prospective Study. J. Immunother, 2024, vol. 47 (6), pp. 227–231.
7. Espeland K., Christensen E., Aandahl A. et al. Extracorporeal photopheresis with 5-aminolevulinic acid in crohn’s disease-a first-in-human phase I/II study. J. Clin. Med, 2024, vol. 13 (20), p. 6198.
8. Ertl C., Ruf T., Hammann L. et al. Extracorporeal photopheresis vs. systemic immunosuppression for immune-related adverse events: Interim analysis of a prospective two-arm study. Eur. J. Cancer, 2024, vol. 212, p. 115049.
9. Kil’dyushevskiy A.V., Molochkov A.V., Zhuravlev O.R. et al. Extracorporeal photopheresis in the treatment of the new coronavirus disease COVID-19 (a series of clinical observations). Al’manakh klinicheskoy meditsiny, 2020, vol. 48, special issue 1, pp. 11–19 (in Russ.).
10. Neretin V.Ya., Kil’dyushevskiy A.V., Agafonov B.V. et al. Photopheresis — a new method for treating myasthenia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2002, vol. 103, no. 6, pp. 11–14 (in Russ.).
11. Cavaletti G., Perseghin P., Dassi M. et al. Extracorporeal photochemopherapy reduces the incidence of relapses in experimental allergic encephalomyelitis in DA rats. J. Neurol, 2001, vol. 248 (6), pp. 535–536.
12. Cavaletti G., Perseghin P., Buscemi F. et al. Immunomodulationg effects of extracorporeal photochemotherapy (ECP) in rats experimental allergic encephalomyelitis (EAE). Int. J. Tissue React, 2001, vol. 23 (1), pp. 21–31.
13. Cavaletti G., Perseghin P., Dassi M. et al. Extracorporeal photochemotherapy reduces the severity of Lewis rat experimental allergic encephalomyelitis through a modulation of the function of peripheral blood mononuclear cells. J. Biol. Regul. Homeost. Agents, 2004, vol. 18 (1), pp. 9–17.
14. Cavaletti G., Perseghin P., Dassi M. et al. Extracorporeal photochemotherapy: a safety and tolerability pilot study with preliminary efficacy results in refractory relapsing-remitting multiple sclerosis. Neurol Sci, 2006, vol. 27 (1), pp. 24–32.
15. Neretin V.Ya., Kil’dyushevskiy A.V., Ozerova I.V. et al. Sposob lecheniya bol’nykh autoimmunnymi zabolevaniyami. Rossiyskiy patent 2000 goda po MPK A61M1/38 A61N5/06 2000-11-27. Publikatsiya 1999-01-29 [Method for treating patients with autoimmune diseases. Russian patent of 2000 under IPC A61M1/38 A61N5/06 2000-11-27. Publication 1999-01-29].
16. Neretin V.Ya., Kotov S.V., Kil’dyushevskiy A.V. et al. Ekstrakorporal’naya fotokhimioterapiya v lechenii bol’nykh rasseyannym sklerozom: uchebnoe posobie [Extracorporeal photochemotherapy in the treatment of patients with multiple sclerosis: a tutorial]. Moscow, MONIKI, 2003. 11 p.
17. Ozerova I.V., Kotov S.V., Neretin V.Ya. et al. Ekstrakorporal’naya fotokhimioterapiya v lechenii bol’nykh rasseyannym sklerozom. Materialy k Respublikanskomu rabochemu soveshchaniyu “Voprosy diagnostiki i lecheniya demieliniziruyushchikh zabolevaniy nervnoy sistemy” [Extracorporeal photochemotherapy in the treatment of patients with multiple sclerosis. Materials for the Republican working conference «Issues of diagnostics and treatment of demyelinating diseases of the nervous system»]. Stupino, 23–24 fevralya 1999. Pp. 180–182.
18. Signoriello E., Signori A., Lus G. et al. NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab. Mult. Scler. Relat. Disord, 2024, vol. 87, p. 105594.
19. Pandit L. No evidence of disease activity (NEDA) in multiple sclerosis — shifting the goal posts. Ann. Indian Acad. Neurol, vol. 22 (3), pp. 261–263.
20. Giovannoni G., Singer B. A., Issard D. et al. Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study. Mult. Scler, 2022, vol. 28 (8), pp. 1219–1228.